Alector’s AL002 misses primary endpoint in Alzheimer’s trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Latest Ratings for ALEC
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Stifel | Downgrades | Buy | Hold |
| Feb 2022 | Citigroup | Maintains | Buy | |
| Sep 2021 | William Blair | Initiates Coverage On | Outperform |
